Characterising people with focal drug-resistant epilepsy: A retrospective cohort study
Epilepsy & Behavior · 2023
DOI: 10.1016/j.yebeh.2023.109540 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Epilepsy & Behavior, 2023. Verfasst von Caroline Benoist und 7 weiteren Autor:innen. Beteiligte Einrichtung: Angelini Pharma S.p.A.; Viale Amelia 70, 00181 Rome, Italy. Hauptthemen laut MEDLINE: Epilepsies, Partial, Epilepsy, Drug Resistant Epilepsy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Angelini ACRAF SpA Research Centre, University College London Hospitals Biomedical Research Centre.
Abstract (Originalsprache)
OBJECTIVES: To describe the demographics, clinical characteristics, drug treatment outcomes, healthcare resource utilization, and injuries among people with focal drug-resistant epilepsy (F-DRE) analysed separately for six European countries. METHODS: We used electronic medical record data from six European (Belgium, Spain, Italy, France, UK and Germany) primary care/specialist care databases to identify antiseizure medication (ASM) treatment-naïve people (aged ≥ 18 years at F-DRE diagnosis). They were followed from their epilepsy diagnosis until death, the date of last record available, or study end. We used descriptive analyses to characterise the F-DRE cohort, and results were reported by country. RESULTS: One-thousand-seventy individuals with F-DRE were included (mean age 52.5 years; 55.4 % female). The median follow-up time from the first diagnosis to the end of the follow-up was 95.5 months across all countries. The frequency of F-DRE diagnosis in 2021 ranged from 8.8 % in Italy to 18.2 % in Germany. Psychiatric disorders were the most common comorbidity across all countries. Frequently reported psychiatric disorders were depression (26.7 %) and anxiety (11.8 %). The median time from epilepsy diagnosis to the first ASM failure ranged from 5.9 (4.2-10.2) months in France to 12.6 (5.8-20.4) months in Spain. Levetiracetam and lamotrigine were the most commonly used ASM monotherapies in all countries. Consultation with a general practitioner is sought more frequently after F-DRE diagnosis than after epilepsy diagnosis, except in the UK. SIGNIFICANCE: No one ASM is optimal for all people with F-DRE, and the risks and benefits of the ASM must be considered. Comorbidities must be an integral part of the management strategy and drive the choice of drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Angelini Pharma S.p.A.; Viale Amelia 70, 00181 Rome, Italy.
- IQVIA Solutions; Via Fabio Filzi 29, 20124 Milano; Italy.
- IQVIA Solutions; Via Fabio Filzi 29, 20124 Milano; Italy. Electronic address: franca.heiman@iqvia.com.
- UCL Queen Square Institute of Neurology, London WC1N 3BG, UK; Stichting Epilepsie Instellingen Nederland (SEIN), Heemstede 2103 SW, the Netherlands; Neurology Department, West of China Hospital, Sichuan University, Chen…
Förderung
- Angelini ACRAF SpA Research Centre
- University College London Hospitals Biomedical Research Centre
Zitieren
APA
Benoist, C., Boccaletti, S., Leach, J. P., Cattaneo, A., Chaplin, A., Antunes, L., Heiman, F., & Sander, J. W. (2023). Characterising people with focal drug-resistant epilepsy: A retrospective cohort study. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2023.109540
Vancouver
Benoist C, Boccaletti S, Leach JP, Cattaneo A, Chaplin A, Antunes L, et al. Characterising people with focal drug-resistant epilepsy: A retrospective cohort study. Epilepsy & Behavior. 2023. doi:10.1016/j.yebeh.2023.109540
BibTeX
@article{Benoist2023,
author = {Benoist, Caroline and Boccaletti, Simona and Leach, John Paul and Cattaneo, Agnese and Chaplin, Anna and Antunes, Luis and Heiman, Franca and Sander, Josemir W},
title = {Characterising people with focal drug-resistant epilepsy: A retrospective cohort study},
journal = {Epilepsy & Behavior},
year = {2023},
doi = {10.1016/j.yebeh.2023.109540}
}
EUVIMED